Orrin M Troum, MD
Orrin Troum, MD, is a Clinical Professor of Medicine, Division of Rheumatology, at the Keck School of Medicine, University of Southern California. He received his undrgraduate degree in biology at Tulane University, New Orleans, LA. He attended the Autonomous University of Guadalajara, School of Medicine and the College of Medicine and Dentistry of New Jersey prior to completing his internship/residency in internal medicine and fellowship in rheumatology at Los Angeles County/USC Medical Center. He is board certified in internal medicine and rheumatology.
Dr Troum pioneered the use of extremity MRI in the evaluation, clinical decision process and outcome of patients with inflammatory arthritis. He is a founding member and past-President of the International Society of Musculoskeletal Imaging in Rheumatology. He has also served on the ACR Imaging Task Force and is a reviewer of the imaging abstracts for the ACR’s Annual National Meeting. Dr Troum is a founding Fellow of the American College of Rheumatology and a member of the Southern California Rheumatology Society (past-President 1999-2000), California Rheumatology Alliance, Philadelphia Rheumatism Society, the American Society of Bone and Mineral Research and Osteoarthritis and Research Society International.
He served as Acting Clinical Director of Rheumatology at LAC/USC prior to starting his rheumatology private practice in 1986. In 2014, he joined the Providence St John’s Health Center as a Board of Director’s member of The Doctors of St John’s Medical Group. Additionally, he was on the Board of Directors (2003–2007) and currently serves on the public policy & advocacy committee of the Arthritis Foundation. Dr Troum clinical research focuses on rheumatoid arthritis and other inflammatory arthropathies, osteoarthritis, osteoporosis, and metabolic disorders.
Consultancy – AbbVie, Amgen, BMS, Pfizer, Roche/Genentech; Speaker bureau – AbbVie, Amgen, BMS, Celgene, Novartis, Pfizer, Roche/Genentech, Takeda; Grant Support – AbbVie, Amgen, BMS, Centocor, CORRONA, Novartis, Pfizer, R-Pharm; Stock/equity – Theralogix